Koichi Ichimura
Juntendo University
7 Papers
8 Citations
Koichi Ichimura is an academic researcher from Juntendo University. The author has contributed to research in topics: Medicine & Temozolomide. The author has an hindex of 1, co-authored 7 publications. Previous affiliations of Koichi Ichimura include National Cancer Research Institute.
Chat about Author
Papers
Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yuki Yamagishi,Yuki Yamagishi,Nobuyoshi Sasaki,Yoshiko Nakano,Yuko Matushita,Takaki Omura,Saki Shimizu,Kuniaki Saito,Keiichi Kobayashi,Yoshitaka Narita,Akihide Kondo,Yoshiaki Shiokawa,Motoo Nagane,Koichi Ichimura +13 more
TL;DR: In this article, a clinically applicable protocol for determining mutations in myd88 in the CSF of patients with CNS lymphoma was established, and the conditions to judge mutation were rigorously determined.
34
Identification of novel SSX1 fusions in synovial sarcoma.
Akihiko Yoshida,Yasuhito Arai,Kaishi Satomi,Takashi Kubo,Eijitsu Ryo,Yuko Matsushita,Yuko Matsushita,Natsuko Hama,Kazuki Sudo,Motokiyo Komiyama,Yasushi Yatabe,Tatsuhiro Shibata,Hitoshi Ichikawa,Koichi Ichimura,Koichi Ichimura,Akira Kawai,Taisuke Mori +16 more
TL;DR: In this article, a subset of SS18 FISH-negative/atypical synovial sarcoma was analyzed using RNA sequencing and monoclonal antibodies that recognize SS18-SSX and the SSX C-terminus.
24
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Shun Yamamuro,Masamichi Takahashi,Kaishi Satomi,Nobuyoshi Sasaki,Tatsuya Kobayashi,Eita Uchida,Daisuke Kawauchi,Tomoyuki Nakano,Tomoyuki Nakano,Takashi Fujii,Takashi Fujii,Yoshitaka Narita,Akihide Kondo,Kojiro Wada,Atsuo Yoshino,Koichi Ichimura,Arata Tomiyama,Arata Tomiyama +17 more
TL;DR: In this article, the authors investigated the antitumor effects of Lomustine (CCNU) and ACNU against TMZ-resistant GBM (TMZ-R-GBM).
17
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma
Kenji Fujimoto,Hideyuki Arita,Hideyuki Arita,Kaishi Satomi,Kai Yamasaki,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Yasuji Miyakita,Toru Umehara,Keiichi Kobayashi,Kaoru Tamura,Shota Tanaka,Fumi Higuchi,Yoshiko Okita,Yonehiro Kanemura,Junya Fukai,Daisuke Sakamoto,Takehiro Uda,Ryunosuke Machida,Aya Kuchiba,Taketoshi Maehara,Motoo Nagane,Ryo Nishikawa,Hiroyoshi Suzuki,Makoto Shibuya,Takashi Komori,Yoshitaka Narita,Koichi Ichimura,Koichi Ichimura +29 more
TL;DR: In this paper, the authors examined the utility of molecular classification based on pTERT status and copy-number alterations (CNAs) in IDH-wildtype lower grade gliomas (LGGs, grade II, and III).
5